RNXT vs APP vs MGNI vs NKTR

For growth investors, AppLovin Corporation (APP) is the stronger pick with 16.

4% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Magnite, Inc. (MGNI) offers the better valuation at 14. 9x trailing P/E (13. 7x forward), making it the more compelling value choice. Analysts rate AppLovin Corporation (APP) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Magnite, Inc.

(MGNI) is the cheapest at 14. 9x versus AppLovin Corporation at 48. 1x. On forward P/E, Magnite, Inc. is actually cheaper at 13. 7x.

Over the past 5 years, AppLovin Corporation (APP) delivered a total return of +744.

2%, compared to -88. 1% for RenovoRx, Inc. (RNXT). Over 10 years, the gap is even starker: APP returned +618. 6% versus RNXT's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), RenovoRx, Inc.

(RNXT) is the lower-risk stock at 1. 17β versus AppLovin Corporation's 2. 24β — meaning APP is approximately 92% more volatile than RNXT relative to the S&P 500. On balance sheet safety, RenovoRx, Inc. (RNXT) carries a lower debt/equity ratio of 6% versus 166% for AppLovin Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AppLovin Corporation (APP) is pulling ahead at 16.

4% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Magnite, Inc. grew EPS 493. 8% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, APP leads at 24. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AppLovin Corporation (APP) is the more profitable company, earning 60.

8% net margin versus -205. 0% for RenovoRx, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APP leads at 75. 8% versus -255. 1% for RNXT. At the gross margin level — before operating expenses — RNXT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Magnite, Inc.

(MGNI) trades at 13. 7x forward P/E versus 29. 4x for AppLovin Corporation — 15. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 79. 9% to $147. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, RenovoRx, Inc.

(RNXT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNXT: -88. 1%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RNXT (Healthcare) and APP (Technology) and MGNI (Communication Services) and NKTR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RNXT is a small-cap quality compounder stock; APP is a mid-cap high-growth stock; MGNI is a small-cap deep-value stock; NKTR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.